A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy

NCT07582133 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

380

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary IgA Nephropathy

Interventions

DRUG: HRS-5965 Capsules

Sponsor

Chengdu Suncadia Medicine Co., Ltd.